'We always have hope that things will be better in the future and that one day we will manage to find a final cure for MS. Until that time, we have to follow the latest research.'
Efforts to improve access to MS treatments continue
New research suggests the rate of brain atrophy, or brain shrinkage, may be an important indicator of disease progression in MS.
Fingolimod has been approved by the US Food and Drug Administration (FDA) as a treatment for children and young people aged 10 years and older with relapsing MS
A phase II trial shows safety and efficacy of amiselimod
Researchers find that suddenly stopping fingolimod may lead to severe worsening of symptoms in MS
Swedish study favours rituximab over fingolimod for those at risk of progressive multifocal leukoencephalopathy
French researchers compare oral and injectable drugs for relapsing-remitting MS
An international study looks at the safety and efficacy of a drug similar to fingolimod
A new trial has failed to show Fingolimod has any effect of in primary-progressive MS
Switching from natalizumab to an alternative drug may prevent disease reactivation
Study shows that switching to natalizumab is more effective than switching to fingolimod
Fingolimod is effective in reducing relapses and brain volume loss
The results suggest that primary progressive and relapsing forms of MS have different underlying mechanisms
Underweight women and patients with low baseline lymphocyte counts should be monitored more closely